Clinical Trials Logo
  1. Home
  2. NSCLC Stage IIIB
  3. NCT03805841

Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions — RAIN  

NSCLC Stage IIIB Clinical Trial

Official title:
Phase 2 Study - Evaluate the Clinical Activity of Tarloxotinib in Patients With Non-Small Cell Lung Cancer That Harbors an EGFR Exon 20 Insertion or HER2-Activating Mutation and Other Advanced Solid Tumors With NRG1/ERBB Family Gene Fusions

Clinical Trial Summary

Open-label, Phase 2, single treatment arm, 3 cohorts

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03805841
Study type Interventional
Source Rain Oncology Inc
Contact
Status Terminated
Phase Phase 2
Start date March 13, 2019
Completion date April 23, 2021
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04042558 - A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies Phase 2
Recruiting NCT04467801 - Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy Phase 2
Active, not recruiting NCT04027647 - Phase 2 Study of Dacomitinib in NSCLC Phase 2
Recruiting NCT04768491 - Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC
Recruiting NCT05132218 - Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer
Recruiting NCT03647956 - Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors Phase 2
Recruiting NCT05281406 - Additional Chemotherapy for EGFRm Patients With the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG) Phase 2
Active, not recruiting NCT04223596 - Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients Phase 2
Recruiting NCT05652868 - Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer Phase 1
Completed NCT00198432 - Chemoradiotherapy of NSCLC Stage IIIB Phase 2
Withdrawn NCT05212922 - A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC Phase 2
Active, not recruiting NCT04932343 - Comparison of Genomic and Transcriptomic Patterns Between CTC and Metastatic Tumormetastatic Tumor
Withdrawn NCT03231475 - Phase I Study of SPH1188-11 in NSCLC Phase 1
Withdrawn NCT03628144 - Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer Phase 2
Recruiting NCT04865250 - Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC Phase 2
Recruiting NCT05816499 - Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC) Phase 1/Phase 2
Active, not recruiting NCT03620669 - 1st Line Durvalumab in PS 2 NSCLC Patients Phase 2
Not yet recruiting NCT03594682 - Optimizing the Therapeutic Dose of Apatinib Mesylate Tablets in Patients With Lung Cancer by Dose Titration：A Real World Exploratory Study N/A
Completed NCT03515252 - Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer Phase 1